A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.

@article{Foss2005APT,
  title={A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.},
  author={Francine Mary Foss and Marie France Demierre and Gina DiVenuti},
  journal={Blood},
  year={2005},
  volume={106 2},
  pages={
          454-7
        }
}
Denileukin diftitox, a genetically engineered fusion protein combining the enzymatically active domains of diphtheria toxin and the full-length sequence for interleukin-2 (IL-2), efficiently targets lymphoma cells expressing the high-affinity IL-2 receptor (IL-2R) consisting of the alpha/p55/CD25, beta/p75/CD122, and gamma/p64/CD132 chains. In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, bexarotene, at biologically relevant concentrations of 10(-6) M to 10(-8) M… CONTINUE READING
Highly Cited
This paper has 44 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 22 citations